Literature DB >> 29336655

Reversible cicatricial ectropion associated with EGFR inhibitors.

Stacy Scofield-Kaplan1, James Todaro2, Bryan J Winn1.   

Abstract

The management of cicatricial ectropion resulting from epidermal growth factor receptor (EGFR) inhibitors is unclear. We describe two cases of bilateral cicatricial ectropion following the use of an EGFR inhibitor who were treated with oral doxycycline, topical ophthalmic steroid and antibiotic ointment to the eyelids, and topical facial steroid cream with lubrication. The first case resolved with discontinuation of panitumumab infusions along with institution of the aforementioned regimen. However, it is unclear whether the resolution was from discontinuation of the infusions or from the instituted regimen. The second case resolved without a dose adjustment of cituximab. This case may provide support for the use of this regimen prior to discontinuation of the offending agent, as there was a successful outcome without alteration of the infusions. Additional cases are necessary to determine if this is a successful means of treating bilateral lower-lid cicatricial ectropion from EGFR inhibitors.

Entities:  

Keywords:  Cicatricial ectropion; EGFR inhibitor; doxycycline

Mesh:

Substances:

Year:  2018        PMID: 29336655     DOI: 10.1080/01676830.2017.1423342

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  2 in total

Review 1.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

2.  Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer.

Authors:  Haoxing D Jin; Nathan W Blessing
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.